AstraZeneca Has a Promising Oncology Pipeline

AstraZeneca's Phase III pipeline is growing ahead of plan, chief executive Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.

AstraZeneca’s Phase III pipeline is growing ahead of plan, chief executive Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.

In oncology, olaparib for solid tumours, moxetumomab pasudotox for hairy cell leukaemia and selumetinib for non-small cell lung cancer are expected to be key players. Also showing potential are AZD9291 a ‘third generation’ tyrosine kinase inhibitor for NSCLC, and from AstraZeneca’s biologics R&D arm MedImmune, MEDI4736, a PD-L1 monoclonal antibody that is being studied in patients with advanced solid tumours.

Within AZ’s oncology franchise, the breast cancer portfolio has been targeted for expansion and a raft of new combination therapies is under investigation,. However substantial growth is expected from established agents such as Faslodex (fulvestrant).

Read the full story at:

http://bit.ly/P1u39eSource: PharmaTimes